About Careers Internship MedBlog Contact us

One-Quarter Of Penis Cancer Patients Do Not Get Recommended Treatment

by Hannah Joy on March 16, 2018 at 7:34 PM
One-Quarter Of Penis Cancer Patients Do Not Get Recommended Treatment

About a quarter of patients with cancer of the penis were found not receiving the recommended treatment and also had half the survival rate, reveals a new study.

A major international survey was presented at the EAU conference in Copenhagen, finds that non-adherence is partly due to patients refusing treatment, or doctors being reluctant to treat appropriately or being unfamiliar with the best procedures.

Penile Cancer is considered a rare human cancer. Around 1 in 100,000 men contract penis cancer every year in the West (which means that a country such as the UK has around 640 cases per year. The US sees 2320 cases per year), however in recent years this rate has risen by 20% to 25% in many countries, especially in older men.

Cancer of the penis is extremely distressing. As the American Cancer Society says "cancer of the penis can be a frightening prospect. Partially or completely removing the penis is often the most effective way to cure penile cancer, but for many men this cure seems worse than the disease".

In this large international survey, researchers found that a significant minority (25%) of patients do not receive the recommended treatment. In part this is due to patients being reluctant to go ahead with surgery which removes all or part of the penis, in part due to doctors not proceeding with the appropriate surgery to treat this rare cancer.

Researchers from 12 centers in Italy, Spain, the USA, Brazil, and Hungary, looked at adherence to the EAU guidelines on treatment of penile cancer. They retrospectively examined the records of 425 patients who had been treated in the 2010-2016 period. Lead author, Dr Luca Cindolo (Abruzzo, Italy) said:

"We found that most patients were treated in accordance with the gold-standard EAU recommendations, but around 25 percent of patients had not received appropriate treatment. From our work, we see that around twice as many patients survive if they have been treated according to recommended guidelines.

In around half of those patients not treated according to guidelines, the decision was made by the doctor, and we suspect that this is because many doctors are unfamiliar with treating this rare, but devastating cancer. In one in 6 cases, the patient, or the patient's carers, made the decision not to be treated according to guidelines. We often find that patients don't want to be treated, or that the patients' carers are unwilling to take the decision to treat".

These are often difficult treatment decisions to take, and so they need to be arrived at after open discussion between the patient and the medical team. It's a condition which most urologists don't see very often, so it's best if the medical team is experienced in dealing with the condition. This may mean that the treatment in national or international centers of excellence is the best way to proceed".

Commenting, Dr Vijay Sangar (Director of Surgery, Christie Hospital, Manchester) said:

"We often find that patients with rare cancers get short-changed because the cancer is so seldom encountered by doctors. We can suggest that if we treat rare cancers in national or even international centers of excellence, the chances of better management improve.

In the UK for example, we centralized the treatment of penis cancer into just 10 centers of excellence, whereas in some countries such as Hungary, Spain, and Italy, these rare urological cancers are still treated locally, which may reflect the lower survival rates.

Generally, the more penile cancer a team sees the better they become at managing the disease. The recently established eUROGEN consortium will make a huge difference to European patient care; this gives patients with rare urological diseases access to the best management no matter where they are in Europe".

Source: Eurekalert
Font : A-A+


Recommended Readings

Latest Cancer News

Personalized Vaccine and T Cell Therapy for Ovarian Cancer Patients
The combination of the personalized cancer vaccine with ACT led to ovarian cancer control in few patients within a span of three months, stated study results.
Kinase-Targeted Therapy Revolutionizes Colorectal Cancer Care
Uncovering key kinases in tumor growth and invasion is crucial for improving targeted therapies in advanced-stage colorectal cancer.
Novel Photo-Oxidation Therapy Holds Promise for Anticancer Treatment
The study findings validate metal-enhanced photo-oxidation for future metal-based anticancer drugs.
Mutations in 11 Genes Linked to Aggressive Prostate Cancer
Mutations in 11 genes are linked to aggressive forms of prostate cancer, which may present novel therapeutic and therapy options.
Link Between Poor Oral Health and Head & Neck Cancer Survival Uncovered
Improved oral health, as indicated by the count of natural teeth and dental appointments preceding the diagnosis, correlated with enhanced head and neck cancer survival rates.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
Greetings! How can I assist you?MediBot

One-Quarter Of Penis Cancer Patients Do Not Get Recommended Treatment Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests